Thermo Fisher Scientific’s Clinical Research Business Honored by CRO Leadership Awards for 12^th Consecutive Year

WILMINGTON, N.C. (May 3, 2023) – The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been recognized for excellence in the 2023 CRO Leadership Awards, which names industry leaders based on a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.

Recognized as a global industry leader, the PPD clinical research business provides clinical development, analytical, and patient and advisory services from early development through regulatory approval and market access. The business helps customers accelerate development from scientific idea to approved medicine and provides product lifecycle management, while ensuring patient safety and data integrity.

“We are honored to receive this important recognition for yet another year, as it reflects our dedication to serving customers to help deliver life-changing therapies to patients,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “We remain committed to providing exceptional customer service through our comprehensive capabilities, our deep expertise and our unwavering passion for helping patients.”

Utilizing patient-centered strategies and data analytics, the business covers multiple therapeutic areas, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites, comprehensive laboratory services, innovative and decentralized trial designs, and a purpose-built delivery model for biotech customers.

In the 2023 CRO Leadership Awards, which recognize high-performing companies for exceptional customer service, the business earned recognition for its capabilities – including access to patient populations, data management and patient recruitment – and for compatibility, including responsiveness, project communications and customer service. In addition, the business was recognized for its reliability and expertise.

The CRO Leadership Awards program is a partnership between Life Science Connect publications Clinical Leader and Life Science Leader, and Industry Standard Research (ISR), the organization’s research affiliate. Each year, ISR assesses approximately 50 clinical research organizations (CROs) on multiple performance metrics in its annual CRO Quality Benchmarking survey. Survey participants included respondents from pharma and biotech companies who have worked directly with CROs. As an honoree, the PPD clinical research business will be featured in the 2023 CRO Leadership Awards issue in June.

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media Contact Information
Nadine Maeser
919-558-4779
Nadine.maeser@ppd.com